6-chloro-2,2-dimethyl-7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one | 136545-08-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 6-chloro-2,2-dimethyl-7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one
• 英文别名: 6-chloro-2,2-dimethyl-7-nitro-4H-1,4-benzoxazin-3-one
• CAS: 136545-08-9
• 化学式: C₁₀H₉ClN₂O₄
• 分子量: 256.645
• InChiKey: CMOPEBFPBQXXGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-chloro-2,2-dimethyl-7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one 在 racemic-2-(di-tert-butylphosphino)-1,1′-binaphthyl 、 palladium diacetate 、 sodium hydride 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 、 mineral oil 为溶剂， 反应 54.5h， 生成 6-methoxy-2.2.4-trimethyl-7-nitro-2H-benzo[b][1.4]oxazin-3(4H)-one
  参考文献：
  名称：

  [EN] AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS
  [FR] DÉRIVÉS AMINOPYRIMIDINIQUES UTILISÉS COMME MODULATEURS DE LRRK2

  摘要：

  式(I)的化合物或其药用可接受的盐，其中A、X、R1、R2、R3和R4如本文所定义。还公开了制备这些化合物的方法，并将这些化合物用于治疗与LRRK2受体相关的疾病，如帕金森病。

  公开号：

  WO2013079505A1
• 作为产物：
  描述：

  2-氨基-4-氯-5-硝基苯酚 在 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 6-chloro-2,2-dimethyl-7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one
  参考文献：
  名称：

  Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer

  摘要：

  Prostate cancer is a commonly diagnosed cancer and a leading cause of cancer-related deaths. The bromodomain and extra terminal domain (BET) family proteins have emerged as potential therapeutic targets for the treatment of castration resistant prostate cancer. A series of 2,2-dimethy1-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives were designed and synthesized as selective bromodomain containing protein 4 (BRD4) inhibitors. The compounds potently inhibit BRD4(1) with nanomolar IC50 values and exhibit high selectivity over most non-BET subfamily members. One of the representative compounds 36 (Y08060) effectively suppresses cell growth, colony formation, and expression of androgen receptor (AR), AR regulated genes, and MYC in prostate cancer cell lines. In in vivo studies, 36 demonstrates a good PK profile with high oral bioavailability (61.54%) and is a promising lead compound for further prostate cancer drug development.

  DOI：

  10.1021/acsmedchemlett.8b00003

文献信息

• [EN] NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2017012647A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds according to Formula (I), wherein R1, R3, R4, R5, L1, and Cy are as defined herein. The present invention also provides compounds, methods for the production of said compounds of the invention, pharmaceutical compositions comprising the same and their use in allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 and/or interferons. The present invention also methods for the prevention and/or treatment of the aforementioned diseases by administering a compound of the invention.

  本发明公开了根据式（I）的化合物，其中R1、R3、R4、R5、L1和Cy如本文所定义。本发明还提供了该发明的化合物、制备该化合物的方法、包括相同化合物的药物组合物以及它们在过敏或炎症症状、自身免疫疾病、增殖性疾病、移植排斥、涉及软骨周转障碍的疾病、先天软骨畸形和/或与IL6和/或干扰素过度分泌相关的疾病中的使用。本发明还提供了通过给予该发明的化合物来预防和/或治疗上述疾病的方法。
• Novel Potassium Channel Activators. II. Synthesis and Pharmacological Evaluation of 3,4-Dihydro-2H-1,4-benzoxazine Derivatives: Modification of the Aromatic Part.
  作者：Yuzo MATSUMOTO、Ryuji TSUZUKI、Akira MATSUHISA、Noriyuki MASUDA、Yoko YAMAGIWA、Isao YANAGISAWA、Tadao SHIBANUMA、Hiroyuki NOHIRA

  DOI：10.1248/cpb.47.971

  日期：——

  Three new series of analogues related to 3, 4-dihydro-2H-1, 4-benzoxazine derivative 1a were synthesized and evaluated for their potassium channel activating activity. In the first series I, where the 6, 7-positions were disubstituted, it was found that an electron-withdrawing substituent was preferable at the 6 position, bet either an electron-withdrawing or releasing substituent without bulkiness was tolerated at the 7 position. In the second series II, where several heterocycles were introduced into the 6, 7-positions, the oxadiazole derivative 6 showed more potent activity than cromakalin. In the third series III, where the benzene ring was replaced by pyridine ring, borane complex 16 had equivalent activity to cromakalim. Especially, compound 6 showed a potent hypotensive effect with a long duration of action in the spontaneous hypertensive rat and had a lesser increasing effect on intracranial pressure in dogs than 1a and levcromakalim, showing a good profile as a antihypertensive agent.

  合成了三种与3, 4-二氢-2H-1, 4-苄氧噻唑衍生物1a相关的类化合物，并评估了它们的钾通道激活活性。在第一系列I中，6、7位被二取代，发现6位最好用一个电子吸引取代基，而7位则可以容忍一个无大体积的电子吸引或释放取代基。在第二系列II中，6、7位引入了几种杂环，氧氮杂环衍生物6的活性比克罗马克林更强。在第三系列III中，将苯环替换为吡啶环，硼烷复合物16的活性与克罗马卡林相当。特别是，化合物6在自发性高血压大鼠中显示了显著的降压效果，并且对犬的颅内压力的增加效应较1a和左克罗马卡林小，表现出良好的抗高血压药物特性。
• Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents
  申请人：Iijima Toru

  公开号：US20090023716A1

  公开（公告）日：2009-01-22

  The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]: wherein Ring A is a benzene ring optionally having a substituent(s) other than R 1 etc, R 1 is a group of the formula: R a SO 2 NH— etc, R a is an alkyl group etc, R 2 and R 3 are each a hydrogen atom, a phenyl group, an optionally substituted alkyl group etc, X is an oxygen atom etc, Y is a group of the formula: —C(═O)— etc, Ar is an optionally substituted aryl group or an optionally substituted heteroaryl group, Q is a single bond, an alkylene group etc, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，可用作矿物质皮质激素受体调节剂，其化学式如下[I]：其中，环A是苯环，可选地具有除R1等之外的取代基；R1是公式RaSO2NH-等的基团；R是烷基等；R2和R3分别是氢原子，苯基，可选地取代的烷基等；X是氧原子等；Y是公式-C（=O）-等的基团；Ar是可选地取代的芳基或可选地取代的杂环基；Q是单键，烷基等，或其药学上可接受的盐。
• Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US08188073B2

  公开（公告）日：2012-05-29

  The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]: wherein Ring A is a benzene ring optionally having a substituent(s) other than R1 etc, R1 is a group of the formula: RaSO2NH— etc, Ra is an alkyl group etc, R2 and R3 are each a hydrogen atom, a phenyl group, an optionally substituted alkyl group etc, X is an oxygen atom etc, Y is a group of the formula: —C(═O)— etc, Ar is an optionally substituted aryl group or an optionally substituted heteroaryl group, Q is a single bond, an alkylene group etc, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，可用作矿物质皮质激素受体调节剂，其化学式如下[I]：其中，环A是苯环，可选地具有除R1等以外的取代基；R1是公式RaSO2NH-等的基团，Ra是烷基等；R2和R3分别是氢原子、苯基、可选地取代的烷基等；X是氧原子等；Y是公式-C（═O）-等的基团；Ar是可选地取代的芳基或可选地取代的杂环基团；Q是单键、烷基等，或其药学上可接受的盐。
• BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS
  申请人：IIJIMA Toru

  公开号：US20110251185A1

  公开（公告）日：2011-10-13

  The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]: wherein Ring A is a benzene ring optionally having a substituent(s) other than R 1 etc, R 1 is a group of the formula: R a SO 2 NH— etc, R a is an alkyl group etc, R 2 and R 3 are each a hydrogen atom, a phenyl group, an optionally substituted alkyl group etc, X is an oxygen atom etc, Y is a group of the formula: —C(═O)— etc, Ar is an optionally substituted aryl group or an optionally substituted heteroaryl group, Q is a single bond, an alkylene group etc, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，其具有以下式[I]，可用作矿物质皮质激素受体调节剂： 其中，环A是苯环，可选择具有取代基(R1等)以外的取代基；R1是公式RaSO2NH-等的基团；R是烷基等；R2和R3分别是氢原子、苯基、可选择取代的烷基等；X是氧原子等；Y是公式-C(═O)-等的基团；Ar是可选择取代的芳基或可选择取代的杂环基；Q是单键、烷基等；或其药学上可接受的盐。